References
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. J Am Med Assoc. 1998. doi:10.1001/jama.279.15.1200
- Carrasco-Garrido P, De Andrés LA, Barrera VH, De Miguel GÁ, Jiménez-García R. Trends of adverse drug reactions related-hospitalizations in Spain (2001–2006). BMC Health Serv Res. 2010. doi:10.1186/1472-6963-10-287
- Charlesworth CJ, Smit E, Lee DSH, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988–2010. J Gerontol A Biol Sci Med Sci. 2015;70:989–995. doi:10.1093/gerona/glv01325733718
- Jain S, Jain P, Sharma K, Saraswat P. A prospective analysis of drug interactions in patients of intensive cardiac care unit. J Clin Diagn Res. 2017. doi:10.7860/JCDR/2017/23638.9403
- Jain KK. Applications of AmpliChip CYP450. Mol Diagn. 2005;9:119–127.16271013
- Swen, J. J., et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin Pharmacol Ther. 2011;89:662–673. doi:10.1038/clpt.2011.3421412232
- Caudle, K. E., et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15:209–217. doi:10.2174/138920021566614013012491024479687
- Whirl-Carrillo, M., et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414–417. doi:10.1038/clpt.2012.9622992668
- Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007. doi:10.1046/j.1365-2125.1999.00073.x
- Tatro DS. Drug Interaction Facts 2014 : The Authority on Drug Interactions. Philadelphia: Lippincott Williams & Wilkins; 2013.
- Hansten PD. TOP 100 Drug Interactions : A Guide to Patient Management. Clearwater, FL: H & H PUBLISHING CO; 2014.
- Phansalkar, S., et al. Drug–drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. J Am Med Informatics Assoc. 2013;20:489–493. doi:10.1136/amiajnl-2012-001089
- FDA. FDA Recommendations for Aripiprazole. Silver Spring, MD: FDA.gov; 2012.
- FDA. FDA Recommendations for Brilinta. Silver Spring, MD: FDA.gov; 2012.
- Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor leads to statin-induced rhabdomyolysis: a case report. Am J Case Rep. 2017;18:1238–1241. doi:10.12659/AJCR.90597429167415
- Arumugam GP, Sundravel S, Shanthi P, Sachdanandam P. Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab. 2006;24:243–247. doi:10.1007/s00774-005-0678-416622738
- FDA. FDA recommendations for paroxetine. Web; 2012 Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/ucm088676.pdf. Accessed May 5, 2019.
- FDA. RIFADIN ® (Rifampin Capsules USP) and RIFADIN ® IV (Rifampin for Injection USP); Silver Spring, MD: FDA.gov; 2010.
- Sales GS, Tobella JS. Nutrigenética y nutrigenómica. in Medicina Personalizada Posgenómica. Conceptos Prácticos Para Clínicos. 2010. doi:10.1016/B978-84-458-2025-4.00008-5
- Klein TE, Ritchie MD. PharmCAT: a pharmacogenomics clinical annotation tool. Clin Pharmacol Ther. 2018;104:19–22. doi:10.1002/cpt.v104.129194583
- Caroli J, Sorrentino G, Forcato M, Del Sal G, Bicciato S. GDA, a web-based tool for genomics and drugs integrated analysis. Nucleic Acids Res. 2018;46:W148–W156. doi:10.1093/nar/gky43429800349
- Cheng, R., et al. Virtual pharmacist: a platform for pharmacogenomics. PLoS One. 2015;10:e0141105. doi:10.1371/journal.pone.012049126496198